Rare
lephants
Screener
Toggle theme
Corcept Therapeutics Inc.
CORT
·
Healthcare, Drug Manufacturers - General, United States
Financial Statements
Profitability
Balance Sheet
Cash Flow
Price Ratios
Share-Based Metrics
Valuation
Cash Flow History
Net Cash Flow Breakdown
Net Cash Flow
Cash Flow
›
Net Cash Flow Breakdown
Net Cash Flow Breakdown
Chart
Table
FY2025
FY2024
FY2023
FY2022
FY2021
FY2020
FY2019
FY2018
FY2017
FY2016
FY2015
Total Cash from Operations:
$115.7M
Line Item
Value
% of Total
Capital Expenditures
$0
0.0%
Other Investing
$0
0.0%
Stock Repurchases
$23.7M
20.5%
Other
$81.4M
70.4%
Net Cash Flow
$10.6M
9.1%
